Sign in
Taking people in United StatesPhase 3

Tests VX-880 in adults with type 1 diabetes who had a kidney transplant

Tests VX-880 in adults with type 1 diabetes who received a kidney transplant.

Key facts

Who runs it
Vertex Pharmaceuticals Incorporated
Where
Madison, Philadelphia, and Pittsburgh, United StatesSee the 3 sitesAlso in 2 other countries, 4 sites
Trial code
Registry title
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Status
Recruiting
Phase
Phase 3
People taking part
10 people, planned
Started
31 Mar 2025
Expected to end
17 Sept 2027
Type of study
Interventional
Treatments tested
  • Biological/Vaccine
Record updated
23 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes who have had a kidney transplant. It tests a treatment called VX-880.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Type 1 diabetes with at least 5 years of needing insulin, and a kidney transplant.
Earlier treatment
Must have been on a stable anti-rejection medicine regimen of tacrolimus plus mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks. Must not have had an islet cell transplant, another organ transplant besides kidney, or cell therapy (except a pancreas graft that failed within the first 4 weeks).

Main reasons for not taking part

  • Prior islet cell transplant
  • Organ transplant other than kidney
  • Prior cell therapy
  • More than 1 kidney transplant procedure

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
  • Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
  • Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Who cannot take part

  • Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
  • Participants had >1 kidney transplant procedure; Other protocol defined Inclusion/Exclusion criteria may apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

Also in 2 other countries, 4 sites

  • UW University Hospital - EndocrinologyMadison, United StatesTaking people
  • Perelman Center for Advanced Medicine - EndocrinologyPhiladelphia, United StatesTaking people
  • Montefiore Clinical and Translational Research Center - EndocrinologyPittsburgh, United StatesTaking people

About the trial

What the trial wants to find out

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

The group in the trial

  • VX-880Treatment being tested

    Treatment: Biological/Vaccine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
Plain-language title
Tests VX-880 in adults with type 1 diabetes who had a kidney transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06832410, who can take part
Record updated
23 March 2026